Ladarixin
- Generic Name
- Ladarixin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H12F3NO6S2
- CAS Number
- 849776-05-2
- Unique Ingredient Identifier
- DEH7Q6472O
- Background
Ladarixin is under investigation in clinical trial NCT04628481 (A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual Β-Cell Function).
- Associated Conditions
- -
- Associated Therapies
- -
Ladarixin With Sotorasib in Advanced NSCLC - Phase II
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT05815186
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
Ladarixin With Sotorasib in Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 40
- Registration Number
- NCT05815173
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Dompé Farmaceutici S.p.A
- Target Recruit Count
- 2
- Registration Number
- NCT05368402
- Locations
- 🇮🇹
Ospedale F. Spaziani Frosinone, Frosinone, Italy
🇮🇹Università Campus Bio-Medico di Roma (UCBM) Policlinico Universitario, Rome, Italy
Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Dompé Farmaceutici S.p.A
- Registration Number
- NCT05035368
- Locations
- 🇺🇸
Institute of Cellular Therapeutics Allegheny Health Network, Pittsburgh, Pennsylvania, United States
A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Dompé Farmaceutici S.p.A
- Target Recruit Count
- 25
- Registration Number
- NCT04899271
- Locations
- 🇩🇪
Institut fuer Diabetes forschung in Muenster (IDFM), Muenster, Germany
🇮🇹Universitá degli Studi di Milano - Ospedale Luigi Sacco, Milan, Italy
🇩🇪Universitaetsklinikum Gessen und Marburg GmbH - Medizinische Klinik und Poliklinik III, Glessen, Germany
A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Dompé Farmaceutici S.p.A
- Target Recruit Count
- 36
- Registration Number
- NCT04854642
- Locations
- 🇨🇭
CROSS Research S.A., I Unit, Arzo, Canton Ticino, Switzerland
A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function
- Conditions
- Interventions
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Dompé Farmaceutici S.p.A
- Target Recruit Count
- 140
- Registration Number
- NCT04628481
- Locations
- 🇺🇸
Atlanta Diabetes Associates (ADA), Atlanta, Georgia, United States
🇺🇸UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇧🇪Universitair Ziekenhuis Brussel (UZB), Jette, Belgium
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Dompé Farmaceutici S.p.A
- Target Recruit Count
- 76
- Registration Number
- NCT02814838
- Locations
- 🇩🇪
Med. Klinik und Poliklinik 3, Universitätsklinikum Giessen und Marburg GmbH, Giessen, Germany
🇧🇪Universitair Ziekenhuis Brussel Diabetes Clinic, Brussels, Belgium
🇧🇪Universitair Ziekenhuis Leuven Campus Gasthuisberg Endocrinology, Leuven, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.